U
Ultima Genomics
DNA sequencing with its UG 100™ platform, delivering ultra‑high throughput and cost‑effective omics solutions that aim to make the $100 genome a reality
About Ultima Genomics
Ultima Genomics is a pioneering company in the genomics industry, dedicated to advancing human health through innovative genomic sequencing technologies. The company operates in the high-throughput genomics market, which involves processing large volumes of genetic data to uncover insights into human biology and disease. Ultima Genomics serves a diverse range of clients, including academic researchers, pharmaceutical companies, and healthcare providers, who require comprehensive and precise genomic data for their work.
The core of Ultima Genomics' business model is its revolutionary sequencing architecture, which significantly enhances the breadth, depth, and frequency of genomic data collection. "Breadth" refers to the ability to gather extensive data from each sample, "depth" means detecting even the smallest genetic variations, and "frequency" involves conducting routine tests for early disease detection and monitoring. By excelling in these areas, Ultima Genomics provides its clients with unparalleled access to high-quality genomic information.
Ultima Genomics generates revenue by offering its advanced sequencing services and technologies to clients who need detailed genomic data for research and clinical applications. The company also partners with other organizations to drive forward the scale of genomic information, enabling groundbreaking discoveries and improvements in human health. By continuously innovating and expanding its capabilities, Ultima Genomics aims to help its customers achieve what was previously considered impossible in the field of genomics.
In summary, Ultima Genomics is at the forefront of the genomics revolution, providing cutting-edge sequencing solutions that empower researchers and healthcare professionals to make significant strides in understanding and treating diseases.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Fremont, United States
- Sector
- Health Tech & Medtech
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Khosla Ventures
Lightspeed Venture Partners
National Human Genome Research Institute
National Institutes of Health
Series B and later8 investors entered at this stage
Founders Fund
Lightspeed
Playground Global
General Atlantic
Andreessen Horowitz
aMoon Fund
Marius Nacht
D1 Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
67 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ultima Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ultima Genomics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
